Abiomed's Heart Pump Can Improve Outcomes in Some Patients

The use of Abiomed's (NASDAQ: ABMD) Impella heart pumps reduced the rate of death, stroke, myocardial infarction, and repeat procedures in high-risk percutaneous coronary intervention (PCI) patients, according to a new study.

The interim data from the healthcare company's single-arm PROTECT III study reflects patient outcomes for 1,143 patients who underwent elective non-emergent PCI with an Impella pump between March 2017 and September 2019.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source Fool.com